Predictive health company Potrero Medical said yesterday it closed a $26.6 million Series C funding to help support commercialization of its flagship Accuryn monitoring system.
The San Francisco-based company’s Accuryn system is designed to use urinary catheters as diagnostic tools. The device provides real-time measurements of intra-abdominal pressure, urine output and core body temperature and can be integrated into hospital EMR systems, the company said.
Financing in the round was led by GT Healthcare Capital Partners and Sonder Capital, Potrero Medical said.
“We are excited to be a part of Potrero Medical’s vision, which has the potential to extend beyond the intensive care unit into areas such as the cardiac catheterization lab and operating room,” GT Healthcare managing partner & founder Alan Au said in a press release.
Potrero said that funds will be used to help support continued commercialization of the Accuryn monitor and for the development of an artificial intelligence platform intended to aid in the identification of life-threatening events, such as acute kidney injury.
“As robotics advanced medicine by improving minimally invasive surgery, predictive health is revolutionizing the way physicians monitor and treat their patients. Potrero Medical is leading the way with the Accuryn monitoring system. Using artificial intelligence and data analytics, the Accuryn system will be a transformative advancement in predictive health,” Intuitive Surgical founder & Auris Health CEO Dr. Frederic Moll, who joined Potrero’s board, said in a prepared statement.
“At Potrero, we are not only focused on the 300,000 people that lose their life due to AKI, but also focused on their families. We have a technology that enables medical teams to proactively treat patients, so that patients can return to their normal lives with their families. We are thankful for the support of our investors and our shared commitment to transforming patient care through predictive health,” Potrero CEO Joe Urban said in a prepared release.